Navigation Links
In-Vivo Gene Therapy Technique to Cure XSCID in Basset Pups

X-linked severe combined immunodeficiency (XSCID) is a genetic disorder which completely affects the immune system. In case basset pups which suffered from XSCID in-vivo gene //therapy was successfully used to cure this life threatening disease. The researchers from the University Of Pennsylvania School Of Veterinary Medicine and the National Institute of Allergy and Infectious Disease introduced a retro virus which acts as a vector for the correct gene of XSCID.

The results of their study were presented in the journal Blood. In humans; XSCID affects one in 100,000 boys, resulting from the inheritance of a faulty gene on one of the mother's X-chromosomes. It often proves fatal before the child's first birthday. The disease first came to public attention in the late 1970s with the ‘Bubble Boy,’ David Vetter, who lived his entire life in a sterilized environment in order to protect him from outside germs. Vetter died in 1984. The only treatment for XSCID is through a bone-marrow transplant from a normal donor designed to replenish the hematopoietic stem cells that are capable of constantly renewing new functional immune cells, or, more recently, gene therapy that works by replacing the defective gene with a normal gene in the patients own cells.

Gene therapy has been put to curative use against this disease in humans resulting in successful immune reconstitution in 10 of 11 boys in a 1999 French study. This clinical trial consisted of the standard ex-vivo approach to gene therapy in which bone-marrow cells were taken out of the body of the affected boy, cultured in vitro for five days with exposure to a retroviral vector containing the normal gene and transplanted back into the patient. Three of the boys unfortunately developed a T-cell leukemia attributed to the gene therapy resulting in the cessation of this study. ‘Although ex-vivo gene therapy has been shown to be capable of restoring normal immune function in XSCID boys, there are severa l potential problems with this approach,’ said Peter J. Felsburg, professor of immunology at Penn's School of Veterinary Medicine. ‘The number of gene-corrected bone- marrow stem cells that can be transplanted back into the patient is limited to correcting the potentially low number of bone-marrow stem cells harvested from the patient. In addition, the manipulation and culturing of the cells outside the body may alter their ability to provide for long-term generation of new immune cells.’

The Penn researchers and their NIAID colleagues, led by Drs. Suk See Ting-De Ravin and Harry L. Malech took a different approach by directly injecting the retrovirus vector containing the corrective gene into the bloodstream of XSCID dogs with the hope of correcting the defective hematopoietic stem cells within the patient. The therapy completely restored immune function in three of the four dogs the researchers treated. The fourth dog received the lowest dose of the retrovirus vector the virus that had been engineered to pass on the gene leading Felsburg and his colleagues to believe that there is a lower limit to the dose before the treatment becomes effective. Since the boys involved in the French gene-therapy study did not develop leukemia until more than three years after the treatment began, the researchers have been particularly interested in knowing the long-term consequences of the trial. At 16 and 18 months following treatment, the two dogs involved in the long-term study have maintained their immune systems and remain, effectively, cured of XSCID, with no adverse side effects.

‘The results of this study show that this in-vivo approach to gene therapy may be a viable alternative for not only gene therapy of XSCID but perhaps other hematologic and immunologic diseases, thereby eliminating any potential detrimental effects of the ex-vivo manipulation and culture of cells that is required by current clinical gene therapy protocols,’ Felsburg said. ‘In addition, this approach would make it easier to perform gene therapy outside of specialized medical centers.’ Felsburg's research was funded by grants from the National Institute of Allergy and Infectious Disease of the National Institutes of Health.

Source: Eurkalert
'"/>




Related medicine news :

1. Detecting DNA Damage With In-Vivo Alkaline Comet Assay
2. Cancer Doctors Okays Controversial Prostate Therapy
3. Consensus on "Combination Therapy" for Breast Cancer
4. Gene Therapy shows promise in treating Hemophilia
5. "Make AIDS Therapy affordable" - Physicians demand
6. Hormone replacement Therapy a headache
7. Simple Therapy
8. Therapy for stopping the spread of cancer cells
9. Gene Therapy Destroys Pancreatic Cancer Cells
10. Letrozole Beats Tamoxifen in Breast Cancer Therapy
11. Garlic Supplements Impede HIV Therapy
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... ... June 27, 2016 , ... ... technology to revolutionize the emergency ambulance transport experience for the millions of people ... how Uber has disrupted the taxi industry through the use of technology. Now, ...
(Date:6/26/2016)... ... , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center ... Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This annual ... the world’s leading providers of cereal and other breakfast foods. Its residents often refer ...
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new ... affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... Pa. , June 23, 2016 The ... in an outpatient dialysis facility.  Treatments are usually 3 ... 6 hours per visit, including travel time, equipment preparation ... a patient, but especially grueling for patients who are ... of a skilled nursing and rehabilitation centers for some ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... rough waters, but it continues to present great opportunities ... featured companies for today: Intrexon Corp. (NYSE: ... ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), ... Learn more about these stocks and receive your complimentary ...
Breaking Medicine Technology: